In the last year we have seen the publication of multiple guidance documents on the management of heart failure, each setting new standards for the management of HFpEF, including two national guidelines and a consensus statement on the phenotyping of HFpEF. Why do we need so many guidance documents? What was the rationale behind their development? And how concordant are they?
In the final episode of Heart Failure in Focus for 2023, Dr Muthiah Vaduganathan is joined by Prof Giuseppe Rosano (St George’s Hospital London, UK), who played a central part in the development of the 2023 European heart failure guideline focussed update and an earlier publication on HFpEF phenotyping. He shares his thoughts on these aforementioned questions and together with our host, provide a practical interpretation of how to incorporate the three distinct documents into daily practice.
Questions can be sent via Twitter to our host @mvaduganathan or to @radcliffeCARDIO.
This podcast is supported by an unrestricted educational grant from AstraZeneca.
All content for Heart Failure in Focus is the property of Radcliffe Cardiology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In the last year we have seen the publication of multiple guidance documents on the management of heart failure, each setting new standards for the management of HFpEF, including two national guidelines and a consensus statement on the phenotyping of HFpEF. Why do we need so many guidance documents? What was the rationale behind their development? And how concordant are they?
In the final episode of Heart Failure in Focus for 2023, Dr Muthiah Vaduganathan is joined by Prof Giuseppe Rosano (St George’s Hospital London, UK), who played a central part in the development of the 2023 European heart failure guideline focussed update and an earlier publication on HFpEF phenotyping. He shares his thoughts on these aforementioned questions and together with our host, provide a practical interpretation of how to incorporate the three distinct documents into daily practice.
Questions can be sent via Twitter to our host @mvaduganathan or to @radcliffeCARDIO.
This podcast is supported by an unrestricted educational grant from AstraZeneca.
Until recently, guideline directed medical therapy for HFpEF and HFmrEF was aimed at symptom control with mostly diuretic-based treatments. The publication of EMPEROR-PRESERVED in 2021 prompted changes in the AHA/ACC/HFSA guidelines, assigning a 2a recommendation across the SGLT-2 inhibitor class for use in this patient population. Since then, the heart failure community has been waiting in anticipation for the results of DELIVER – the largest SGLT-2 inhibitor trial in this population to date and viewed by many, as an important validation of this class of medication in HFpEF/HFmrEF.
In this first episode of our new podcast series, Heart Failure in Focus, Dr Muthiah Vaduganathan is joined by Prof Scott Solomon to discuss the DELIVER data which was released at the ESC Congress 2022 in Barcelona. During this fascinating interview, you will get insight into the uniqueness of the DELIVER trial design, the importance of its design for key patient groups and what the results mean for clinical practice.
Questions can be sent via Twitter to our host @mvaduganathan or to @radcliffeCARDIO.
This podcast is supported by an unrestricted educational grant from AstraZeneca.
Heart Failure in Focus
In the last year we have seen the publication of multiple guidance documents on the management of heart failure, each setting new standards for the management of HFpEF, including two national guidelines and a consensus statement on the phenotyping of HFpEF. Why do we need so many guidance documents? What was the rationale behind their development? And how concordant are they?
In the final episode of Heart Failure in Focus for 2023, Dr Muthiah Vaduganathan is joined by Prof Giuseppe Rosano (St George’s Hospital London, UK), who played a central part in the development of the 2023 European heart failure guideline focussed update and an earlier publication on HFpEF phenotyping. He shares his thoughts on these aforementioned questions and together with our host, provide a practical interpretation of how to incorporate the three distinct documents into daily practice.
Questions can be sent via Twitter to our host @mvaduganathan or to @radcliffeCARDIO.
This podcast is supported by an unrestricted educational grant from AstraZeneca.
